Adjuvant Chemotherapy of Breast Cancer

Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1 ¿ 3, 1984
Herausgegeben von Senn, Hans-Jörg

• Broschiertes Buch

Produktbeschreibung

H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Recent Results in Cancer Research .96
• Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
• Artikelnr. des Verlages: 978-3-642-82359-6
• Softcover reprint of the original 1st ed. 1984
• Seitenzahl: 264
• Erscheinungstermin: 15. Dezember 2011
• Englisch
• Abmessung: 244mm x 170mm x 15mm
• Gewicht: 462g
• ISBN-13: 9783642823596
• ISBN-10: 3642823599
• Artikelnr.: 36119237

Inhaltsangabe

Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- The Preclinical Scientific Basis for Adjuvant Chemotherapy in Breast Cancer.- The Clinical-Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- Molecular and Cellular Mechanisms Underlying Ineffective Cancer Chemotherapy.- Impact of Early Detection of Breast Cancer on Adjuvant Chemotherapy.- Contribution of Prognostic Factors to Adjuvant Chemotherapy in Breast Cancer.- Review: Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- Clinical Results I: Experience of Randomized Trials with Surgical Controls.- Scandinavian Trials with a Short Postoperative Course Versus a 12-Cycle Course.- A Brief Overview of Findings from NSABP Trials of Adjuvant Therapy.- CMF Adjuvant Programs at the Milan Cancer Institute.- A Controlled Trial of Adjuvant Chemotherapy with Melphal-an Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer.- Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year Results.- Ludwig Breast Cancer Trial LBCS III: Chemo-and Endocrine Adjuvant Treatment in Postmenopausal Patients.- Postmenopausal Node-Positive Comparison of Observation with CMFP and CMFP + Tamoxifen Adjuvant Therapy An Eastern Cooperative Oncology Group Trial.- Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group's Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients.- Clinical Results II: Experience of Non-Randomized Trials with Historical or Mached Surgical Controls.- FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update.- Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974-1984).- Significance of Drug Dose, Timing and Radiotherapy inAdjuvant Therapy of Breast Cancer.- The Use of a Natural History Data Base to Compare Outcome Among Several Trials of Adjuvant Chemotherapy for Stage II Breast Cancer.- Clinical Results III: Experience of Randomized Trials Without Surgical Controls.- Adjuvant Systemic Therapy in Postoperative Node-Positive Patients with Breast Carcinoma: The CALGB Trial and the ECOG Premenopausal Trial.- Adjuvant Therapy of Breast Cancer: A Southwest Oncology Group Experience.- Short- or Long-term Chemotherapy for Node-Positive Breast Cancer: LMF 6 Versus 18 Cycles. SAKK Study 27/26.- Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer: Preliminary Analysis of 5-Year Results.- Review: Experience of Randomized Trials Without Surgical Controls.- Remaining Problems of Adjuvant Chemotherapy in Breast Cancer.- Second Malignant Neoplasms in Operable Carcinoma of the Breast.- Tamoxifen and Combination Chemotherapy as Adjuvant Treatment in Postmenopausal Women with Breast Cancer.- Ludwig Breast Cancer Trials LBCS III and IV: Adjuvant Endocrine Treatment in Postmenopausal Patients.- Problems of Combined Adjuvant Radiochemotherapy.- The Present Dilemma of Adjuvant Chemotherapy: Acceptance and Risks Versus Benefits.- Are Current Worldwide Studies Going to Answer the Important Questions Remaining in Adjuvant Chemotherapy of Breast Cancer?.- Closing Remarks and Outlook.- Closing Remarks and Outlook.